<DOC>
	<DOCNO>NCT02145611</DOCNO>
	<brief_summary>Cardiovascular disease major public health problem country . Among cause cardiovascular disease High Blood Pressure ( HBP ) Diabetes Mellitus ( DM ) . Type 2 diabetes ( DM2 ) associate twofold risk cardiovascular disease , endothelial dysfunction early marker vascular complication . There evidence action glucagon-like peptide 1 ( GLP-1 ) endothelial cell vascular smooth muscle . Vildagliptin drug use treatment DM2 able prolong activity GLP-1 , improve glycemic control endothelial function . Objectives : To evaluate effect vildagliptin endothelial function patient DM2 hypertension use Endo-PAT 2000 device .</brief_summary>
	<brief_title>Vildagliptin vs. Glibenclamide Endothelial Function Type 2 Diabetes Hypertension</brief_title>
	<detailed_description>Material Methods 1 . Population Subjects select accord inclusion criterion : age 35 year , history type 2 diabetes mild hypertension ( blood pressure &lt; 160 X 100 mmHg ) long 15 year , body mass index &lt; 35 Kg/m2 , glycated hemoglobin ( HbA1c ) 7,0 e 10,5 % . Exclusion criterion : smoking within last six month , pregnancy breastfeeding ; creatinine clearance &lt; 45 ml/min/m2 ( MDRD ) ; use NPH ( neutral protamine Hagedorn ) or/and regular insulin , pioglitazone , GLP-1 receptor agonist , DPP-4 inhibitor acarbose ; serum alanine aminotransferase aspartate aminotransferase level 3 time upper limit normal range ; subject ischemic heart disease , cerebrovascular disease , atherosclerotic disease , cancer , heart failure functional class II , III IV ; stress test typical chest pain ST segment depression ≥ 1 mm , horizontal descendent duration 0.08 second J point ; use 3 anti hypertensive drug , characterize resistance hypertension ; intolerance metformin , inability give inform consent . 1.2 Sample size To calculate number patient use site : www.lei.dante.br-pesquisa . The sample compose 25 patient arm . The number patient per group necessary detect difference reactive hyperemia index ( RHI ) 0.3 power 80 % 25 patient . And two-tailed test 5 % level calculate 21 , SD 0.35 difference RHI . The RHI improvement 0.3 base previous study drop rate 20 % consider . Fifty diabetic hypertensive patient randomize first visit , submit endothelial function test Endo-PAT 2000 device , divide 2 group : group 1 receive vildagliptin ( 100 mg/day , divide 2 time ) added-on metformin ( 500 2550 mg/day , accord glycemic control ) group 2 receive glibenclamide ( 5 20 mg/day , accord glycemic control ) added-on metformin . Blood sample collect 12-hour overnight fast screen visit 12 week treatment vildagliptin ( group 1 ) glibenclamide ( group 2 ) . At screening , renin angiotensin system blocker add subject , antihypertensive drug maintain . All patient give inform consent study approve local Institutional Review Board . 1.3 Blood Pressure The blood pressure ( BP ) measurement technique make accord VI Brazilian Guidelines Hypertension Treatment : 1 ) measurement take recently calibrate aneroid sphygmomanometer know accurate ; 2 ) cuff place low edge 3 cm elbow crease bladder center brachial artery ; 3 ) standard bladder use ( 12-13 cm long 35 cm wide ) , large small bladder available thicker thinner arm , respectively ; 4 ) arm bare support blood pressure cuff position heart level ; 5 ) mean three BP measurement take sit position 5 10 minute rest use ; 6 ) phase I V ( disappearance ) Korotkoff sound used identify systolic diastolic BP , respectively ; 7 ) pressure increase rapidly 30 mmHg level radial pulse extinguish ; 8 ) cuff deflation rate 2 mmHg per beat use ; 9 ) minimum 1-minute interval recommend reading avoid venous congestion ; 10 ) BP measure arm detect possible difference due peripheral vascular disease ; case , high value take reference one . Hypertension define systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg current use anti-hypertensive drug . 1.3 Anthropometric Measure Weight height measure anthropometric scale body mass index ( BMI ) obtain formula : BMI = weight ( Kg ) / ( height meter ) 2 . 1.4 Randomisation A computer-generated randomisation list deliver Research Center glibenclamide/vildagliptin group . 2 . Laboratory Blood sample drawn 12 hour fast measure triglyceride , total cholesterol HDL-cholesterol , glycemia , serum creatinine , ultrasensitive reactive C protein ( RCP ) , Alanine aminotransferase HbA1c . Microalbuminuria also evaluate . Diabetic subject identify history diabetes dietetic treatment diabetes use hypoglycemic drug . Subjects consider diabetic 2 fast glucose 125 mg/dl , accord National Diabetes Data Group . Serum cholesterol evaluate accord Brazilian Guideline Dyslipidemia . Low density lipoprotein cholesterol ( LDLc ) calculate Friedewald formula triglyceride ( TG ) level 400 mg/dL ( LDLc = TC - HDLc - TG/5 ( para TG &lt; 400 mg/dL ) . Total Cholesterol ( TC ) ; high density lipoprotein cholesterol ( HDLc ) . 3 . Treadmill test At screen visit select subject submit coronary disease evaluation stress test . Subjects stress test typical chest pain ST segment depression ≥ 1 mm , horizontal descendent duration 0.08 second J point exclude . 4 . Endothelium function Pulse amplitude tonometry ( Endo-PAT 2000 ; Itamar Medical , Caesarea , Israel ) peripheral endothelium function test , non-invasive determination digital endothelium function . This test perform follow light breakfast morning 20 min rest patient supine position . The PAT device place tip index finger comprise pneumatic pletysmography applies uniform pressure surface distal finger , allow measurement pulse volume change . The inflation pressure digital device electronically set 10 mmHg diastolic blood pressure 70 mmHg . The PAT signal record baseline follow 5 min arterial occlusion use inflatable cuff , contralateral arm serf control . The blood pressure cuff inflate 60 mmHg high systolic pressure least 200 mmHg 5 min . Lack residual pulsatility monitor throughout occlusion period . The post-occlusive hyperemia stimulate endothelium-dependent vasodilatation , cause increase digital pulse amplitude . Pulse amplitude record electronically finger analyse computerise , automate algorithm ( Itamar Medical ) . The change baseline measurement express reactive hyperemia index ( RHI ) , part reflect vasodilator function digital microcirculation . Subjects instruct fast start night test refrain ingest alcohol caffeine . Room temperature maintain time study 21º C 24° C ; restrictive clothing could interfere blood flow arm , watch ring jewellery hand remove . The patient comfortably seat allow lie study room least 15 min reach relaxed cardiovascular steady-state . The subject study submit endothelium function test first visit 12 week treatment . Endothelial dysfunction define 2.34±0.33 less 2 standard deviation ( SD ) 20 healthy asymptomatic control individual without history cardiovascular disease without major risk factor , correspond RHI ≤ 1,6837 . 5 . Central Arterial Pressure The applanation tonometry radial artery non-invasive method assess arterial stiffness , predictive vascular disease . A portion artery pressure wave travel towards extremity reflect back peripheral impedance point . In healthy individual , reflect wave return aorta diastole . When arteries become stiff , transit time de incident reflect wave reduce . Thus , reflect wave return aorta systole cardiac cycle augment central blood pressure . This augmenting central pressure quantify augmentation index ( AIx ) . AIx associate cardiovascular risk , predict presence absence coronary artery disease40 . Higher value AIx indicate increase wave reflection periphery earlier return reflect wave result increase pulse velocity , contribute increase arterial stiffness . In young healthy individual , systolic arterial pressure ( aortic ) 20 mmHg less peripheral systolic pressure ( brachial ) . The applanation tonometry radial artery perform randomised subject first visit 12 week treatment . Statistical analysis The continuous variable analyze use Student 's t-test analysis variance ( ANOVA ) . Data present mean ± 1 SD continuous variable frequency categorical variable . The chi-squared test utilized comparative study group use vildagliptin use glibenclamide . Logistical regression perform association statistical significance . An alpha error 5 % consider acceptable give significance p-value &lt; 0.05 . Pharmacovigilance requirement : Any serious adverse event report Ethics Committee FAMERP within 24 hour occurrence . All serious adverse event also report Novartis Drug Safety &amp; Epidemiology ( DS &amp; E ) within 24 hour investigator ( designee ) aware serious adverse event . Specific definition adverse event , serious adverse event , outline , along report criterion require Novartis . Adverse event ( AE ) Information AEs , whether volunteered patient , discover investigator question , detected physical examination , laboratory test mean , collect record Adverse Event Case Report Form follow appropriate . An AE undesirable sign , symptom medical condition occur start study treatment , even event consider treatment-related . Study treatment include study medication evaluation , reference placebo drug ( therapy ) give phase trial . Medical conditions/diseases present start study treatment consider adverse event worsen start study treatment ( procedure specify protocol ) . Adverse event ( serious adverse event ) occur start study treatment signing informed consent form record Medical History/Current Medical Conditions Case Report Form . Abnormal laboratory value test result constitute adverse event induce clinical sign symptom , consider clinically significant require therapy , record Adverse Events Case Report Form sign , symptom diagnosis associate . As far possible , adverse event also describe : 1. duration ( start end date ) , 2. severity grade ( mild , moderate , severe ) , 3. relationship study drug ( suspect / suspect ) , 4. action ( ) take .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>1. old 35 year ; 2. history type 2 diabetes mellitus mild hypertension ( blood pressure &lt; 160 x 100 mmHg ) short period time 15 year ; 3. body mass index &lt; 35 Kg/m2 ; 4. plasma concentration glycated hemoglobin 7.0 10.5 % 1. smoking last 6 month ; 2. gestation ; 3. breastfeeding ; 4. creatinine clearance &lt; 45 ml / min / m2 ( MDRD ) ; 5. use type insulin , pioglitazone , receptor agonist GLP1 , dipeptidyl peptidase ( DPP4 ) inhibitor acarbose ; 6. serum alanine aminotransferase aspartate aminotransferase three time upper limit method ; 7. individual cancer , heart failure functional class II , III IV , ischemic heart disease , cerebrovascular atherosclerotic ; 8. individual positive exercise test coronary disease , characterize STsegment depression ≥ 1 mm , horizontal downward duration 0.08 second J point typical chest pain test ; 9. individual use 3 antihypertensive drug , characterize resistant hypertension ; 10. intolerance metformin ; 11. individual unable give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>hypertension , diabetes , endothelial function</keyword>
</DOC>